Abuse drugs and derivatives

(1R,2S)-(-)-Ephedrine, 1g

(1R,2S)-(-)-Ephedrine-d6 hydrochloride (dimethyl-d

(1R,2S)-(-)-Ephedrine-d6 hydrochloride (dimethyl-d

(1R,2S)-(-)-Ephedrine hydrochloride, 1g

(1R,2S)-(-)-Ephedrine hydrochloride, 1000µg/ml in MeOH, 1ml

(1R,2S)-(-)-Ephedrine hydrochloride

(1R,2S)-(-)-Ephedrine

(1R,2R)-(-)-Pseudoephedrine, 1g

(1R,2R)-(-)-Pseudoephedrine-d3 HCl (N-methyl-d3)

(1R,2R)-(-)-Pseudoephedrine

(1-Naphthalenyl)-(1-(5-fluoropentyl)-1H-indol-3-yl

(1-Naphthalenyl)-(1-(5-fluoropentyl)-1H-indol-3-yl

(1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanone-d9

(1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanone

(1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanone

(1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanone

(1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanone

(1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-)-napht

(1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-)-napht

(±)-Zopiclone-d8 (piperazinyl-d8)

(±)-Zopiclone-d8 (piperazinyl-d8)

(±)-Zopiclone-13C4 (piperazinyl-13C4)

(±)-Zopiclone-13C4 (piperazinyl-13C4)

(±)-trans-Hexahydrocannabinol (Mix of 9R & 9S diastereomers), 10000µg/ml in MeOH, 1ml